Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer

Oppenheimer lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $21 from $23 and keeps an Outperform rating on the shares after the company announced year-end results and provided a business update. Total revenues, anchored by Danyelza, came in at $88M, consistent with January guidance. Management guided to 2025 total revenues being flat to lower, $75-90M vs. more optimistic Oppenheimer and consensus’ estimates of $97.5 and $104M, respectively, prior to the announcement. The firm views the planned Q2 clinical data and strategy update for the SADA platform as critical to shifting focus to the radiopharmaceutical pipeline.